Table 1

Clinical and demographic features from patients within the PARA cohort (n=148) with rheumatoid arthritis

Mean age, years (SD)33.2 (3.5)
Median gestational age, weeks (IQR)39 (38–40)
Mean disease duration, years (SD)6.4 (5.8)
Rheumatoid factor positive, n (%)106 (71.6)
ACPA positive, n (%)92 (62.2)
Nulliparity, n (%)73 (49.3)
Erosions, n (%)89 (60.1)
Smoking, n (%)13 (8.8)
Education, years (SD)15.5 (2.9)
Medication use postpartum (any use, n (%)):

  • Prednisone

61 (41.2)

  • Methotrexate

54 (36.5)

  • Sulfasalazine

49 (33.1)

  • Biological agents*

20 (13.5)

  • Hydroxychloroquine

18 (12.2)

  • Azathioprine

2 (1.4)

  • Leflunomide

1 (0.7)

  • *adalimumab n=8, etanercept n=13.

  • ACPA, anti-citrullinated protein antibody; PARA, Pregnancy-induced Amelioration of Rheumatoid Arthritis.